For the year ending 2025-12-31, CNTA made $15,000K in revenue. -$199,031K in net income. Net profit margin of -1326.87%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| License and other revenue | 15,000 | 0 | 6,853 | - |
| Research and development | 172,224 | 150,244 | 124,405 | 155,083 |
| General and administrative | 50,468 | 50,811 | 53,731 | 55,200 |
| Change in fair value of contingent value rights | - | - | 0 | 1,980 |
| Acquired in-process research and development | - | - | - | 0 |
| Loss from operations | -207,692 | -201,055 | -171,283 | -212,263 |
| Interest income | 20,527 | 14,016 | 10,476 | -7,033 |
| Amortization of debt discount | - | - | - | 0 |
| Interest expense | 11,459 | 10,090 | - | - |
| Debt issuance costs | - | - | - | 0 |
| Interest expense | - | - | 9,906 | - |
| Loss on extinguishment of debt | 0 | -34,097 | - | - |
| Other non-operating income (expense), net | 2,911 | -1,687 | -5,428 | 2,342 |
| Loss before income taxes | -195,713 | -232,913 | -176,141 | - |
| Income tax expense | 1,819 | 2,844 | -25,056 | -747 |
| Net loss | -197,532 | -235,757 | -151,085 | -216,207 |
| Foreign currency translation adjustments | 1,045 | 1,223 | 1,700 | -2,185 |
| Unrealized gain on available for sale securities, net of tax of 0.1 million in 2025 and 0.8 million in 2024 | 243 | - | - | - |
| Unrealized gain on available for sale securities, net of taxes | - | 1,497 | 1,290 | - |
| Reclassification adjustment for realized net gain on available for sale marketable securities included in net loss, net of tax of 0.8 million in 2025 and 0.4 million in 2024 | 2,787 | - | - | - |
| Other comprehensive (loss) income | -1,499 | 2,720 | - | - |
| Total comprehensive (loss) income | -199,031 | -233,037 | -148,095 | -218,392 |
| Basic EPS | -1.46 | -2.06 | -1.57 | -2.31 |
| Diluted EPS | -1.46 | -2.06 | -1.57 | -2.31 |
| Basic Average Shares | 135,715,608 | 114,473,449 | 96,177,578 | 93,400,513 |
| Diluted Average Shares | 135,715,608 | 114,473,449 | 96,177,578 | 93,400,513 |
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)